Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 248 entries
View as:

A Study for Dynamic Prediction Model of Breast Cancer Bone Metastases

Phase: N/A Priority: Normal
NCT ID: NCT06544668 Org: User:
Start: 08/06/24 End: 01/20/25 Due: 01/20/26

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Phase: N/A Priority: Normal
NCT ID: NCT06345300 Org: User:
Start: 03/10/24 End: 12/24/25 Due: 12/24/26

A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin

Phase: N/A Priority: Normal
NCT ID: NCT04850040 Org: User:
Start: 05/06/21 End: 12/31/24 Due: 12/31/25

Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM

Phase: N/A Priority: Normal
NCT ID: NCT06543069 Org: User:
Start: 01/31/24 End: 01/31/27 Due: 01/31/28

Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy

Phase: N/A Priority: Normal
NCT ID: NCT06889402 Org: User:
Start: 04/01/25 End: 04/30/25 Due: 04/30/26

Antirotinib Hydrochloride Plus Whole Brain Radiotherapy for Small Cell Lung Cancer With Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT06611657 Org: User:
Start: 08/20/21 End: 07/30/25 Due: 07/30/26

Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT05762900 Org: User:
Start: 10/25/22 End: 10/25/30 Due: 10/25/31

Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06509009 Org: User:
Start: 08/30/24 End: 05/30/27 Due: 05/30/28

A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients

Phase: N/A Priority: Normal
NCT ID: NCT06082557 Org: User:
Start: 10/31/23 End: 06/30/25 Due: 06/30/26

GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06490341 Org: User:
Start: 07/20/24 End: 07/20/27 Due: 07/20/28

Pan-canceR Early-Stage deteCtion by lIquid Biopsy tEchNique projecT

Phase: N/A Priority: Normal
NCT ID: NCT04822792 Org: User:
Start: 03/23/21 End: 06/30/23 Due: 06/30/24

The Impact of Inflammatory Adhesion on the Prognosis of Colon Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT06655285 Org: User:
Start: 10/24/24 End: 10/27/24 Due: 10/27/25

Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT06483672 Org: User:
Start: 07/31/24 End: 12/31/27 Due: 12/31/28

Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy

Phase: N/A Priority: Normal
NCT ID: NCT06317558 Org: User:
Start: 03/01/24 End: 12/31/34 Due: 12/31/35

Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06163729 Org: User:
Start: 08/25/22 End: 05/01/28 Due: 05/01/29

The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06287320 Org: User:
Start: 03/01/24 End: 02/28/26 Due: 02/28/27

Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03775928 Org: User:
Start: 12/18/18 End: 10/01/21 Due: 10/01/22

Goal-directed Enteral Nutritional Perioperative Management

Phase: N/A Priority: Normal
NCT ID: NCT06510543 Org: User:
Start: 03/30/24 End: 05/30/31 Due: 05/30/32

The Influence of Treatment Position (Prone vs. Supine) on Whole Breast Target

Phase: N/A Priority: Normal
NCT ID: NCT05609058 Org: User:
Start: 01/01/19 End: 11/01/23 Due: 11/01/24

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT06452433 Org: User:
Start: 06/01/24 End: 02/02/28 Due: 02/02/29

Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ

Phase: N/A Priority: Normal
NCT ID: NCT06761846 Org: User:
Start: 01/31/25 End: 12/31/27 Due: 12/31/28

Hypofractionated Radiotherapy for HNSCC in Elderly Patients

Phase: N/A Priority: Normal
NCT ID: NCT06768125 Org: User:
Start: 01/01/24 End: 12/30/26 Due: 12/30/27

Toripalimab for High-risk Locally Advanced Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06416696 Org: User:
Start: 01/09/24 End: 12/31/26 Due: 12/31/27

Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC

Phase: N/A Priority: Normal
NCT ID: NCT05541445 Org: User:
Start: 08/01/22 End: 12/01/24 Due: 12/01/25

Multi-center Study of Deep Learning AI in Breast Mass

Phase: N/A Priority: Normal
NCT ID: NCT05443672 Org: User:
Start: 08/12/21 End: 08/31/23 Due: 08/31/24